8-K: PDS Biotech's VERSATILE-002 Trial Shows Strong Survival

PDS Biotechnology announced final topline survival data from its VERSATILE-002 Phase 2 trial, showing a median overall survival of 39.3 months in HPV16-positive head and neck cancer patients.

Summary

• PDS Biotechnology announced final topline survival data from its VERSATILE-002 Phase 2 clinical trial.
• The trial evaluated PDS0101 (Versamune HPV) in combination with Keytruda (pembrolizumab) for HPV16-positive first-line recurrent and/or metastatic head and neck squamous cell cancer (1L R/M HNSCC).
• The median overall survival (mOS) was 39.3 months in patients with CPS ≥ 1.
• This mOS compares favorably to the best published result of 17.9 months for standard of care pembrolizumab or pembrolizumab + chemotherapy.
• The lower limit of the 95% confidence interval for mOS is 23.9 months, with the upper limit not yet estimable.
• The combination therapy was well tolerated, with no patients discontinuing the trial due to treatment-related adverse events.
• Durable patient survival was attributed to high levels of long-lasting, multifunctional HPV16-specific CD8+ T cells induced by PDS0101.
• The company plans to publish the full data set for this trial later this year.
• A VERSATILE-003 Phase 3 trial is currently in progress.

Sentiment

Score: 9

Explanation: The clinical trial results show a highly significant improvement in median overall survival compared to the current standard of care, coupled with a favorable safety profile. This is a major positive development for the company and patients.

Positives

• Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 significantly exceeds the best published standard of care of 17.9 months.
• The treatment combination of PDS0101 + Keytruda was well tolerated, with no patients discontinuing due to treatment-related adverse events.
• The therapy promotes durable patient survival through high levels of long-lasting, multifunctional HPV16-specific CD8+ T cells.
• Survival outcomes were consistent across various patient demographics and clinical characteristics.
• PDS Biotech believes these results position them for leadership in the rapidly growing HPV16-positive HNSCC market.

Negatives

• No head-to-head studies have been performed comparing pembrolizumab and PDS0101, meaning the comparison to standard of care is indirect.

Risks

• Ability to protect intellectual property rights.
• Anticipated capital requirements and dependence on additional financing, which may restrict operations or require relinquishing rights.
• Limited operating history in the current line of business, making it difficult to evaluate prospects.
• Timing, future success, and cost of clinical trials for PDS0101, PDS01ADC, PDS0103, and other Versamune-based product candidates.
• Successful implementation of research and development programs and collaborations, and the interpretation of their results.
• Ability to continue as a going concern.
• Legislative, regulatory, political, and economic developments outside the company's control.

Future Outlook

PDS Biotech is well-positioned for leadership in the largest and most rapidly growing segment of HNSCC in the US and Europe. The company anticipates publishing the full data set for the VERSATILE-002 trial later this year and is progressing with the VERSATILE-003 Phase 3 trial. They believe PDS0101 brings new hope to HPV16-positive head and neck cancer patients.

Management Comments

• "We believe this final readout of topline survival data from our VERSATILE-002 clinical trial supports the durable clinical effect of PDS0101 with similarly promising survival outcomes reported in two other recently published studies, the IMMUNOCERV study, and the NCI-led study in HPV16-positive recurrent and/or metastatic cancers." Dr. Kirk Shepard, M.D., Chief Medical Officer.
• "We believe PDS0101, which is simple and easy to administer, brings new hope to the rapidly growing population of HPV16-positive head and neck cancer patients. We look forward to publishing the full data set for this trial later this year." Dr. Kirk Shepard, M.D., Chief Medical Officer.
• "With PDS0101 plus pembrolizumab, an added benefit appears to be that the combination is well tolerated, and no patients discontinued the trial due to treatment-related adverse events." Frank Bedu-Addo, PhD, President and Chief Executive Officer.

Industry Context

HPV16-positive HNSCC represents a significant and rapidly growing unmet medical need. The development of targeted therapies like PDS0101 to treat the underlying cause of the disease is crucial. The positive results from VERSATILE-002 suggest a potential new standard of care in an area where oncologists prioritize therapies offering the best chance for survival.

Comparison to Industry Standards

• The median overall survival (mOS) of 39.3 months for PDS0101 + Keytruda in patients with CPS ≥ 1 significantly surpasses the best published result of 17.9 months for standard of care pembrolizumab or pembrolizumab + chemotherapy.
• This comparison highlights a substantial improvement over current benchmarks for first-line recurrent and/or metastatic HPV16-positive head and neck squamous cell cancer.

Stakeholder Impact

• Shareholders: Highly positive impact due to significantly improved clinical trial results, potentially leading to increased stock value and market leadership.
• Patients: Offers new hope and a potentially more effective and well-tolerated treatment option for HPV16-positive head and neck squamous cell cancer.
• Oncologists: Provides a promising new therapeutic approach that could become a preferred treatment option given its efficacy and safety profile.
• Regulatory Authorities: The strong data may facilitate future regulatory approvals for PDS0101.

Next Steps

• Publish the full data set for the VERSATILE-002 trial later this year.
• Continue the VERSATILE-003 Phase 3 trial.
• Advance PDS0101 in a pivotal clinical trial for advanced HPV16-positive head and neck squamous cell cancers.
• Continue evaluating PDS01ADC in multiple Phase 2 trials for various cancer indications.

Key Dates

Recommendation

The final topline survival data from the VERSATILE-002 Phase 2 trial demonstrates a median overall survival of 39.3 months, which is more than double the best published standard of care (17.9 months). This significant improvement in efficacy, combined with a favorable safety profile (no treatment-related discontinuations), positions PDS0101 as a potential game-changer in the treatment of HPV16-positive head and neck squamous cell cancer. The ongoing Phase 3 trial and the company's stated goal for market leadership further reinforce the strong upside potential, making it a compelling "strong buy" for investors.

Keywords

PDS Biotechnology, PDSB, VERSATILE-002, Phase 2, clinical trial, HPV16-positive, head and neck squamous cell cancer, HNSCC, PDS0101, Versamune HPV, Keytruda, pembrolizumab, median overall survival, mOS, immunotherapy, oncology, cancer treatment